SCHEMBL255003

SCHEMBL255003

CC(C)=CCC/C(C)=C/CC/C(C)=C/CBr

nearest known ligand 0.73

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.73
MAPT P10636 2/20 0.64
MEN1 O00255 2/20 0.64
CYP3A4 P08684 2/20 0.64
ALOX15 P16050 2/20 0.64
ALDH1A1 P00352 1/20 0.64
UGT1A1 P22309 1/20 0.64
SQLE Q14534 7/20 0.61
KDM4E B2RXH2 1/20 0.57
FNTA P49354 1/20 0.52
FNTB P49356 1/20 0.52
ICMT O60725 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9238573 1.00 KMT2A (0.73) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL158266 1.00 KMT2A (0.73) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL16485660 1.00 KMT2A (0.73) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL1586840 1.00 KMT2A (0.73) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL2250076 1.00 KMT2A (0.73) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL158315 1.00 KMT2A (0.73) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL11844736 1.00 KMT2A (0.73) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL11844741 1.00 KMT2A (0.73) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL442001 1.00 KMT2A (0.73) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL12293765 1.00 KMT2A (0.73) KMT2AMAPTMEN1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400529-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA STEALTH BIOTHERAPEUTICS INC. (US) 2024-12-05 US disclosed
US-20240368098-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA STEALTH BIOTHERAPEUTICS INC. (US) 2024-11-07 US disclosed
US-20240293339-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF VARIOUS MITOCHONDRIAL DISEASES OR DISORDERS, INCLUDING FRIEDREICH'S ATAXIA Stealth Bio Therapeutics Inc. (US) 2024-09-05 US disclosed
EP-4034547-B9 ANTIBIOTIC COMPOUNDS UNIV LEIDEN (NL) 2024-09-04 EP disclosed
US-12049455-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia STEALTH BIOTHERAPEUTICS INC. (US) 2024-07-30 US disclosed
EP-4393913-A1 PROCESS FOR THE PREPARATION OF DELTA-TOCOTRIENOL Peptinovo Biopharma Inc. (US) 2024-07-03 EP disclosed
WO-2024126392-A1 VECTORIZED NHC IRIDIUM(III) COMPLEXES AND USE THEREOF IN PHOTODYNAMIC THERAPY AND/OR DIAGNOSTIC CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2024-06-20 WO disclosed
EP-4385995-A1 VECTORIZED NHC IRIDIUM(III) COMPLEXES AND USE THEREOF IN PHOTODYNAMIC THERAPY AND/OR DIAGNOSTIC Centre National de la Recherche Scientifique (FR) 2024-06-19 EP disclosed
EP-4034547-B1 ANTIBIOTIC COMPOUNDS UNIV LEIDEN (NL) 2024-05-22 EP disclosed
EP-4351547-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF VARIOUS MITOCHONDRIAL DISEASES OR DISORDERS, INCLUDING FRIEDREICH'S ATAXIA Stealth BioTherapeutics Inc. (US) 2024-04-17 EP disclosed
EP-0356866-A2 Phosphorus-containing squalene synthetase inhibitors and method E.R. SQUIBB & SONS, INC. (US) 1990-03-07 EP disclosed
US-4871721-A HYPOCHOLESTEROLEMIC AGENTS E. R. SQUIBB & SONS, INC. (US) 1989-10-03 US disclosed
EP-0324421-A2 Phosporus-containing squalene synthetase inhibitors, new intermediates and method E.R. Squibb & Sons, Inc. (US) 1989-07-19 EP disclosed
US-4709079-A ANTI-INFLAMMATORY AGENT EISAI CO., LTD. (JP) 1987-11-24 US disclosed
US-4595783-A Magnesium chloride or phosphonium halide derivatives of 3,7,11-trimethyl-dodeca-2,6(10)-diene(triene)-1-ol VOGEL FRIEDRICH (US) 1986-06-17 US disclosed
US-4576963-A ANTIINFLAMMATORY, ANTIARTHRITIC, ANTIRHEUMATIC EISAI CO., LTD. (JP) 1986-03-18 US disclosed
US-4544758-A Vitamin E intermediates and methods for the preparation of (2R,4'RS,8'RS)-α-tocopherol and (all-rac)-α-tocopherol via the new intermediate products BASF AKTIENGESELLSCHAFT (DE) 1985-10-01 US disclosed
US-4455316-A Polyprenyl esters of acemethacins and anti-inflammatory method of use thereof EISAI CO., LTD. (JP) 1984-06-19 US disclosed
US-4001339-A INSECTICIDES HOFFMANN-LA ROCHE INC. (US) 1977-01-04 US disclosed
US-3944531-A P-ALKOXY-BENZALDEHYDES, INSECTICIDE HOFFMANN-LA ROCHE INC. (US) 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293339-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF VARIOUS MITOCHONDRIAL DISEASES OR DISORDERS, INCLUDING FRIEDREICH'S ATAXIA AIFM2, FH, FECH KMT2A 3296/4885MAPT 322/4885MEN1 2003/4885
US-20240400529-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA FH, COQ8A, TFAM KMT2A 2420/4885MAPT 1057/4885MEN1 4392/4885
US-12049455-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia FH, COQ8A, TFAM KMT2A 2420/4885MAPT 1057/4885MEN1 4392/4885
US-20240368098-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA FH, COQ8A, TFAM KMT2A 2420/4885MAPT 1057/4885MEN1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.